Reuters logo
2 months ago
BRIEF-Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies
June 12, 2017 / 8:24 PM / 2 months ago

BRIEF-Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies

June 12 (Reuters) - Merck & Co Inc:

* Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda® (pembrolizumab) in combination with other therapies

* Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda (pembrolizumab) in combination with other therapies

* Merck & Co Inc - patients currently enrolled in the two studies will continue to receive treatment

* Merck & Co Inc - other studies of keytruda continue unchanged

* Says ‍has accepted external data monitoring committee recommendation to pause new enrollment on keynote-183 and keynote-185​

* Says ‍pause is to allow for additional information to be collected to better understand more reports of death in keytruda groups​

* Merck & Co Inc - accepted external data monitoring committee recommendation to pause new enrollment on keynote-183 and keynote-185 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below